Core Insights - The chemical pharmaceutical sector experienced a slight increase of 0.45% on October 16, with Sunflower leading the gains [1] - The Shanghai Composite Index closed at 3916.23, up 0.1%, while the Shenzhen Component Index closed at 13086.41, down 0.25% [1] Stock Performance - Sunflower (300111) saw a closing price of 9.00, with a significant increase of 10.97% and a trading volume of 4.1856 million shares, amounting to a transaction value of 36.12 billion [1] - Duorui Pharmaceutical (301075) closed at 50.80, up 10.63%, with a trading volume of 74,600 shares and a transaction value of 3.72 billion [1] - Asia-Pacific Pharmaceutical (002370) closed at 7.55, up 10.06%, with a trading volume of 185,700 shares and a transaction value of 1.40 billion [1] - Other notable gainers include Luoxin Pharmaceutical (002793) with a 9.94% increase and a closing price of 5.53, and Saifen Technology (688758) with a 9.02% increase and a closing price of 18.62 [1] Fund Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 18.2269 million from institutional investors, while retail investors saw a net outflow of 83.7 billion [2] - Conversely, speculative funds recorded a net inflow of 855 million [2] Individual Stock Fund Flow - Shutaishen (300204) had a net inflow of 123 million from institutional investors, while retail investors experienced a net outflow of 22.4 million [3] - Baijishenzhou (688235) saw a net inflow of 123 million from institutional investors but a net outflow of 118 million from speculative funds [3] - Xingqi Eye Medicine (300573) recorded a net inflow of 87.1576 million from institutional investors, with retail investors facing a net outflow of 73.7128 million [3]

Core Viewpoint - The A-share market continues to show strength in innovative drug concept stocks, with significant gains observed across multiple companies on October 16 [1] Group 1: Stock Performance - Guizhou BaiLing and Luoxin Pharmaceutical reached the daily limit up [1] - Yifang Bio increased by over 7% [1] - Laime Pharmaceutical, Guangsheng Tang, Anglikang, and Shutaishen all rose by over 6% [1] - Dize Pharmaceutical and Lianhuan Pharmaceutical saw increases of over 5% [1]

Core Points - The company has elected Mr. Ma Shaohong as the employee representative director of the fifth board of directors through a secret ballot at the employee representative meeting held on October 14, 2025 [1] - Mr. Ma meets the qualifications and conditions for directorship as stipulated in relevant laws and regulations [1] - The total number of directors who are also senior management and employee representatives will not exceed half of the total number of directors [1] Meeting Details - The fifth extraordinary general meeting of shareholders was held on October 15, 2025, with a total of 247 participants representing 318,586,520 shares, accounting for 30.0111% of the total voting shares [8] - The meeting was conducted in a combined format of on-site and online voting [6][7] - The meeting adhered to the relevant laws and regulations regarding the convening and holding of shareholder meetings [7] Voting Results - The following proposals were approved during the meeting: - Amendment to the Articles of Association: 303,129,734 votes in favor (95.1483%), 15,440,426 against (4.8465%), and 16,360 abstentions [11] - Amendment to the Rules of Procedure for Shareholders' Meetings: 303,312,134 votes in favor (95.2056%), 15,258,026 against (4.7893%), and 16,360 abstentions [12] - Amendment to the Rules of Procedure for Board Meetings: 303,246,134 votes in favor (95.1849%), 15,324,026 against (4.8100%), and 16,360 abstentions [13] Legal Opinion - The legal opinion provided by the witnessing lawyers confirmed that the procedures for convening and holding the meeting complied with relevant laws and regulations [14]

作者 |郑理 来源 | 独角金融 手握北大双学位、港大金融硕士的"80后"前国泰基金经理姜英，管理公募产品4年后突然转身踏入上市 公司治理层。 10月13日，罗欣药业（002793.SZ）公告称，因工作调动原因，韩风生辞去董事会秘书职务，董事会审 议通过决定聘任姜英为公司董事会秘书。姜英在此之前曾在公募机构国泰基金担任基金经理，2024年离 任，如今从基金经理转向上市公司，相当于换了新的"赛道"。 2022年上半年，她开始管理国泰科创板两年定开、国泰中小盘成长，于2024年12月24日卸任，管理时长 超过两年。截至2024年年末，国泰科创板两年定开、国泰中小盘成长的规模分别约为1.49亿元、4.37亿 元人民币。 图源：公告 基金经理如此选择并不出人意料，近几年，公募基金经理的职业选择早已摆脱"单一化"局限，呈现出日 趋多元化的态势。除了跳槽到其他公募外，他们凭借在公募平台积累的投研能力和客户资源，"公奔 私"是不少资深基金经理的主流选择。如今，越来越多的基金经理跳出资管圈，在不同领域寻找新的机 会。 公开信息显示，姜英1987年10月出生，北京大学理学、经济学双学位本科，北京大学管理学硕士及香港 大学金融学 ...

Core Viewpoint - The company, Luoxin Pharmaceutical (002793), announced the election of Mr. Ma Shaohong as the employee representative director of its fifth board of directors [1] Group 1 - The announcement was made on the evening of October 15 [1] - The election of Mr. Ma Shaohong reflects the company's governance structure and employee representation [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002793 股票简称：罗欣药业 公告编号：2025-094 罗欣药业集团股份有限公司 关于选举职工代表董事的公告 2025 年 10 月 14 日，罗欣药业集团股份有限公司（以下简称"公司"）召 开职工代表大会，通过无记名投票和差额选举的方式，同意选举马少红先生（简 历详见附件）为公司第五届董事会职工代表董事。任期自本次职工代表大会审议 通过之日起至公司第五届董事会任期届满之日止。 马少红先生符合《中华人民共和国公司法》《公司章程》和《董事会议事规 则》中有关董事任职资格和条件的规定。本次职工代表大会选举完成后，董事会 中兼任公司高级管理人员及由职工代表担任的董事人数总计不超过公司董事总 数的二分之一。 特此公告。 罗欣药业集团股份有限公司董事会 2025 年 10 月 15 日 马少红先生，1983 年 08 月出生，中国国籍，无境外永久居留权，济南大学 生物技术专业本科学历。2008 年 07 月至 2009 年 08 月，任山东新发药业有限公 司生物拆分车间线班长；2009 年 09 月至 20 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2025-095 罗欣药业集团股份有限公司 2025 年第五次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 1.会议召集人：罗欣药业集团股份有限公司（以下简称"公司"）董事会； 2.会议主持人：公司董事长刘振腾先生； 3.现场会议召开时间：2025年10月15日（星期三）下午2:00； 4.现场会议召开地点：上海市浦东新区东育路255弄4号前滩世贸中心一期A 栋7层会议室； 5.网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为2025年10月 15日的交易时间，即9:15-9:25，9:30-11:30和13:00-15:00； 特别提示： 1.本次股东大会未出现否决提案的情况； 2.本次会议未涉及变更以往股东大会已通过的决议的情况。 一、会议召开基本情况 （2）通过深圳证券交易所互联网投票系统进行网络投票的开始时间为2025 年10月15日上午9:15，结束时间为2025年10月15日下午3:00。 6.召开方式：现场会议与网络投票相结合的方式。 7.本次 ...

北京市金杜律师事务所上海分所 关于罗欣药业集团股份有限公司 2025 年第五次临时股东大会 之法律意见书 致：罗欣药业集团股份有限公司 北京市金杜律师事务所上海分所（以下简称本所）接受罗欣药业集团股份 有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理 委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国 境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政 区、中国澳门特别行政区和中国台湾省）现行有效的法律、行政法规、规章和 规范性文件和现行有效的《罗欣药业集团股份有限公司章程》（以下简称《公司 章程》）有关规定，指派律师出席了公司于 2025 年 10 月 15 日召开的 2025 年第 五次临时股东大会（以下简称本次股东大会），并就本次股东大会相关事项出具 本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限 于： 1. 经公司 2025 年第三次临时股东大会审议通过的《公司章程》； 2. 公司于 2025 年 9 月 30 日刊登于深圳证券交易 ...

Core Viewpoint - The innovative drug sector experienced a significant rally, with the innovative drug index rising by 2.35% as of the midday close on October 15, 2025, driven by strong performances from various companies [1][2]. Group 1: Market Performance - The innovative drug index (886015.TI) closed at 1366.835, reflecting a gain of 2.35%, equivalent to an increase of 31.422 points [2]. - Notable stock performances included Guangshentang, which surged by 20% to 122.65, and several other companies such as Shutaishen and Anglikang, which saw gains of 14.4% and 10.01%, respectively [2][3]. Group 2: Upcoming Events - The European Society for Medical Oncology (ESMO) conference is set to take place from October 17 to 21, 2025, in Berlin, Germany, where significant clinical research results and data are expected to be disclosed [3][4]. Group 3: Business Development Opportunities - There is growing market anticipation for the release of clinical data from domestic innovative drugs and business development (BD) collaborations, with 83 overseas BD transactions recorded in the first eight months of 2025, totaling 845 billion yuan, marking a 62.81% increase compared to the entire year of 2024 [4]. Group 4: Company Earnings Forecast - Several innovative drug companies are expected to report strong earnings for the third quarter of 2025, with Shengnuo Bio projecting a net profit of 114 million to 140 million yuan, representing a year-on-year increase of 100.53% to 145.10% [5]. - Boteng Co. anticipates a net profit of 73.2 million to 88.2 million yuan, indicating a turnaround from losses, driven by a 17% to 21% increase in revenue [5]. Group 5: Industry Outlook - Analysts express optimism regarding the innovative drug sector, anticipating stabilization and rebound due to upcoming catalysts such as BD and medical insurance negotiations [6]. - Long-term trends indicate that the Chinese pharmaceutical industry has transitioned to new growth drivers, particularly in innovative drugs, which are expected to significantly contribute to the growth of Chinese pharmaceutical companies over the next 5 to 10 years [7].

（文章来源：证券日报） 证券日报网讯 10月14日晚间，罗欣药业发布2025年前三季度业绩预告称，公司预计2025年前三季度归 属于上市公司股东的净利润为2，270万元至2，520万元。 ...